Entity

Time filter

Source Type

London, United Kingdom

Artemis /ˈɑrtɨmɨs/ was one of the most widely venerated of the Ancient Greek deities. Her Roman equivalent is Diana. Some scholars believe that the name, and indeed the goddess herself, was originally pre-Greek. Homer refers to her as Artemis Agrotera, Potnia Theron: "Artemis of the wildland, Mistress of Animals". The Arcadians believed she was the daughter of Demeter.In the classical period of Greek mythology, Artemis was often described as the daughter of Zeus and Leto, and the twin sister of Apollo. She was the Hellenic goddess of the hunt, wild animals, wilderness, childbirth, virginity and protector of young girls, bringing and relieving disease in women; she often was depicted as a huntress carrying a bow and arrows. The deer and the cypress were sacred to her. In later Hellenistic times, she even assumed the ancient role of Eileithyia in aiding childbirth. Wikipedia.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.4-1 | Award Amount: 4.07M | Year: 2013

The overall aim of ASKLEPIOS is to unravel and increase our understanding of the mechanisms that govern pathogenesis of rabies virus (RABV) infection, in pursuit of the rational identification of novel therapeutic leads for rabies encephalitis. Several studies have been conducted over the past decades attempting to unravel the pathogenesis of this deadly disease, however with limited success. New knowledge on the mechanisms of the RABV life-cycle and interaction with the host is needed to identifying clinically applicable therapeutic leads, in search of rational intervention strategies. The project objectives are to: 1. Identify molecules that inhibit RABV replication 2. Identify molecules that inhibit detrimental host responses to RABV infection: 3. Show whether opening the blood-brain-barrier (BBB) improves treatment efficacy: 4. Validate the potential of the molecules identified under 1 and 2 to be used as post-exposure prophylaxis (PEP) when classical PEP is ineffective. In pursuit of these objectives ASKLEPIOS will perform in vitro screening of the anti-viral effect of type-I IFNs, MAP kinase inhibitors and siRNAs. Second, the therapeutic potential of inhibiting the pyroptotic pathway and inflammatory response will be investigated by using inhibitors of caspase-1, IL-1, TNF- IL-6 and MAP kinases. Third, the capacity of molecules to reach the brain will be first evaluated using an efficient in vitro BBB system and in vivo mouse studies.. The most efficient molecule to open the BBB will be co-administrated with the selected therapeutic molecules in the subsequent stages of the project. The results will be collected and synthesized and tested in mice to identify the most effective approach. The ability to clear infection and recover from rabies will be evaluated for each therapeutic scheme identified


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-07-2014 | Award Amount: 20.85M | Year: 2014

COMPARE aims to harness the rapid advances in molecular technology to improve identification and mitigation of emerging infectious diseases and foodborne outbreaks. To this purpose COMPARE will establish a One serves all analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. clinical, epidemiological data) in an integrated inter-sectorial, interdisciplinary, international, one health approach. The framework will link research, clinical and public health organisations active in human health, animal health, and food safety in Europe and beyond, to develop (i) integrated risk assessment and risk based collection of samples and data, (ii) harmonised workflows for generating comparable sequence and associated data, (iii) state-of-the-art analytical workflows and tools for generating actionable information for support of patient diagnosis, treatment, outbreak detection and -investigation and (iv) risk communication tools. The analytical workflows will be linked to a flexible, scalable and open-source data- and information platform supporting rapid sharing, interrogation and analysis of sequence-based pathogen data in combination with other associated data. The system will be linked to existing and future complementary systems, networks and databases such as those used by ECDC, NCBI and EFSA. The functionalities of the system will be tested and fine tuned through underpinning research studies on priority pathogens covering healthcare-associated infections, food-borne disease, and (zoonotic) (re-) emerging diseases with epidemic or pandemic potential. Throughout the project, extensive consultations with future users, studies into the barriers to open data sharing, dissemination and training activities and studies on the cost-effectiveness of the system will support future sustainable user uptake.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.0-1 | Award Amount: 6.97M | Year: 2013

Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to do better than Nature, since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins, ready to commence Phase I clinical trials within 4 years. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e, internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented.


Minazzoli O.,Artemis
Physical Review D - Particles, Fields, Gravitation and Cosmology | Year: 2013

In this paper, we investigate the conservation laws of different types of particles in theories with a universal gravity/matter coupling. The result brings new insight about previous studies on universal gravity/matter theories. Especially, the paper demonstrates that, for perfect fluids, there is an equivalence between the assumption Lm=-Ïμ, where Ïμ is the total energy density, and the assumption that the matter fluid current is conserved [σ(ρuσ)=0, where ρ is the rest mass density]. However, the main result is given in the general case in which one does not make any assumption on the conservation of the matter fluid current. © 2013 American Physical Society. Source


Minazzoli O.,Artemis
Physical Review D - Particles, Fields, Gravitation and Cosmology | Year: 2013

The post-Newtonian parameter γ resulting from a universal scalar-matter coupling is investigated in Brans-Dicke-like scalar-tensor theories where the scalar potential is assumed to be negligible. Conversely to previous studies, we use a perfect fluid formalism in order to get the explicit scalar-field equation. It is shown that the metric can be put in its standard post-Newtonian form. However, it is pointed out that 1-γ could be either positive, null or negative for a finite value of ω0, depending on the coupling function, while scalar-tensor theories without coupling always predict γ<1 for a finite value of ω0. © 2013 American Physical Society. Source

Discover hidden collaborations